3.51
-0.1(-2.77%)
Currency In USD
| Previous Close | 3.61 |
| Open | 3.6 |
| Day High | 3.62 |
| Day Low | 3.48 |
| 52-Week High | 4.02 |
| 52-Week Low | 2.46 |
| Volume | 236,995 |
| Average Volume | 397,385 |
| Market Cap | 274.23M |
| PE | -1.98 |
| EPS | -1.77 |
| Moving Average 50 Days | 3.25 |
| Moving Average 200 Days | 3.2 |
| Change | -0.1 |
If you invested $1000 in Atea Pharmaceuticals, Inc. (AVIR) since IPO date, it would be worth $115.69 as of January 14, 2026 at a share price of $3.51. Whereas If you bought $1000 worth of Atea Pharmaceuticals, Inc. (AVIR) shares 5 years ago, it would be worth $67.37 as of January 14, 2026 at a share price of $3.51.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 12:00 PM GMT
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, to
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
GlobeNewswire Inc.
Dec 22, 2025 12:00 PM GMT
Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, Enrollment Completion Expected Mid-20